Cel Sci Corporation (CVM)

[GD]

If you look at this way, 4 month data analysis indicates "weak"
"muddy" data, like NWBO is doing right, looking for KOL confirmation,
which contradicts your view, IMO. By the way, this is possible
because MK trial has some unqualified patients enrolled which
may messed up the OS data, NWBO's crossover should muddy up the
OS results, IMO. If your view is true of Geert, I do not know
what to say, may be good luck on one person against the whole
industry.